I did not suggest any sales number. I have no idea. But the way the UK Psecials program is set-up by the regulator, for payment, after some due diligence I believe that it is not intended for us as investors or anyone else to know much about what is happening before they are approved.
Moreover, as you know, it is all OUT-OF-POCKET, the UK is a relatively small jurisdiction in terms of potential cases in any one year and the treatment is not approved yet, so not everyone’s personal doctor is going to know about it. So that demand, whatever it is, is not likely a determinant of anything at this stage.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
